Compare HSBC Holdings plc (HSBC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Illumina, Inc. — how do they compare? HSBC Holdings plc trades at $104.11 (market cap $353.82B), while Illumina, Inc. trades at $190.82 (market cap $29.12B). The key difference: HSBC Holdings plc is far larger — about 12.2× Illumina, Inc.'s market cap, and HSBC Holdings plc pays a 3.63% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| HSBC | ILMN | |
|---|---|---|
Market Cap | $353.82B | $29.12B |
Sector | Technology | Health |
52-Week High | $107.86 | $205.10 |
52-Week Low | $63.84 | $91.00 |
Dividend Yield | 3.63% | — |
Enterprise Value | — | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC's stock trades at $103.88, up 0.54% today, with a bullish technical signal from moving averages and support near $103. Recent Q2 2026 earnings beat expectations with a 7% revenue rise to $19 billion (Defense World, 2026-08-06), and the company announced a $1 billion buyback (WSJ, 2026-08-04). Valuation metrics include a P/E of 14.74 and ROE of 12.44%, reflecting solid profitability.
The outlook is positive due to strong earnings momentum and shareholder returns, but risks include a recent analyst downgrade (Citi to 'neutral' on August 5, 2026) and exposure to Asian market volatility. With 38.1% of analysts rating it a buy, the stock offers growth potential tempered by competitive and regulatory headwinds.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
